Molnupiravir, an oral antiviral treatment for COVID-19
covid1.substack.com
Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, Merck reports The antiviral drug molnupiravir reduced the risk of admission to hospital or death by around 50% in non-hospitalised adults who had mild to moderate covid-19 and were at risk of poor outcomes, Merck Sharp and Dohme (MSD) has reported. The company said in a press release that 7.3% of patients (28 of 385) who received molnupiravir as part of the phase III trial and 14.1% of patients taking placebo (53 of 377) either were admitted to hospital or had died by day 29 after randomisation. [
Molnupiravir, an oral antiviral treatment for COVID-19
Molnupiravir, an oral antiviral treatment for…
Molnupiravir, an oral antiviral treatment for COVID-19
Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, Merck reports The antiviral drug molnupiravir reduced the risk of admission to hospital or death by around 50% in non-hospitalised adults who had mild to moderate covid-19 and were at risk of poor outcomes, Merck Sharp and Dohme (MSD) has reported. The company said in a press release that 7.3% of patients (28 of 385) who received molnupiravir as part of the phase III trial and 14.1% of patients taking placebo (53 of 377) either were admitted to hospital or had died by day 29 after randomisation. [